Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,028 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
Hosoda S, Suda G, Sho T, Ogawa K, Kimura M, Yang Z, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N. Hosoda S, et al. Among authors: morikawa k. Liver Cancer. 2022 Oct 31;12(2):156-170. doi: 10.1159/000527759. eCollection 2023 Jun. Liver Cancer. 2022. PMID: 37325489 Free PMC article.
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
Sho T, Suda G, Ogawa K, Kimura M, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Shigesawa T, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N. Sho T, et al. Among authors: morikawa k. Hepatol Res. 2021 Sep;51(9):979-989. doi: 10.1111/hepr.13693. Epub 2021 Jul 20. Hepatol Res. 2021. PMID: 34245216
A pivotal role of Krüppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma.
Maehara O, Sato F, Natsuizaka M, Asano A, Kubota Y, Itoh J, Tsunematsu S, Terashita K, Tsukuda Y, Nakai M, Sho T, Suda G, Morikawa K, Ogawa K, Chuma M, Nakagawa K, Ohnishi S, Komatsu Y, Whelan KA, Nakagawa H, Takeda H, Sakamoto N. Maehara O, et al. Among authors: morikawa k. Cancer Biol Ther. 2015;16(10):1453-61. doi: 10.1080/15384047.2015.1070992. Epub 2015 Jul 15. Cancer Biol Ther. 2015. PMID: 26176896 Free PMC article.
Combination of neutrophil-to-lymphocyte ratio and early des-γ-carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma.
Tsunematsu S, Suda G, Yamasaki K, Kimura M, Takaaki I, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Kamiyama T, Taketomi A, Sakamoto N. Tsunematsu S, et al. Among authors: morikawa k. Hepatol Res. 2017 May;47(6):533-541. doi: 10.1111/hepr.12775. Epub 2016 Aug 11. Hepatol Res. 2017. PMID: 27423140
Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ohara M, Izumi T, Umemura M, Ito J, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Kawagishi N, et al. Among authors: morikawa k. J Viral Hepat. 2017 Dec;24(12):1098-1106. doi: 10.1111/jvh.12737. Epub 2017 Jul 29. J Viral Hepat. 2017. PMID: 28632923
Treatment of hepatitis C in special populations.
Suda G, Ogawa K, Morikawa K, Sakamoto N. Suda G, et al. Among authors: morikawa k. J Gastroenterol. 2018 May;53(5):591-605. doi: 10.1007/s00535-017-1427-x. Epub 2018 Jan 3. J Gastroenterol. 2018. PMID: 29299684 Free PMC article. Review.
Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction.
Sho T, Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Uebayashi M, Terashita K, Kobayashi T, Tsunematsu I, Onodera M, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Kawagishi N, Ohara M, Ono Y, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Sho T, et al. Among authors: morikawa k. Hepatol Res. 2018 Jun;48(7):529-538. doi: 10.1111/hepr.13056. Epub 2018 Feb 15. Hepatol Res. 2018. PMID: 29316051
L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis.
Ohara M, Ogawa K, Suda G, Kimura M, Maehara O, Shimazaki T, Suzuki K, Nakamura A, Umemura M, Izumi T, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ohnishi S, Sakamoto N. Ohara M, et al. Among authors: morikawa k. Hepatol Commun. 2018 Aug 6;2(8):906-918. doi: 10.1002/hep4.1207. eCollection 2018 Aug. Hepatol Commun. 2018. PMID: 30094402 Free PMC article.
Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis.
Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Kimura M, Maehara O, Shimazaki T, Yamamoto K, Shigesawa T, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Suzuki K, et al. Among authors: morikawa k. Hepatol Res. 2019 Nov;49(11):1294-1304. doi: 10.1111/hepr.13399. Epub 2019 Jul 25. Hepatol Res. 2019. PMID: 31260579
1,028 results